Palvella Therapeutics Inc. (PVLA)
PVLA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1583648/000143774924010123/0001437749-24-010123-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PVLA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001583648 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $42.8M |
| Net income | $18.7M |
| Operating income | -$11.9M |
| Net margin | 43.7% |
| Operating margin | -27.7% |
| Revenue growth | +65.3% |
| Cash | $7.3M |
| Total assets | $7.5M |
| P/E (computed) | 113.1× |
| P/S (computed) | 49.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $193.3M cash; operating cash flow -$10.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 14,618,457 (2026-11-02); 11,836,490 a year earlier; 98,851,927 three years earlier. 3y figure adjusted for split (1-for-80 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-80 on 2024-04-23 | Source 2024-04-23 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-02-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-04-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $850K, sold $9.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$24.6M | -$14.4M | $193.3M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$21.9M | -$12.8M | $187.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$15.8M | -$10.9M | $206.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$12.7M | -$4.9M | $58.0M | $18.4M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$11.3M | -$7.9M | $63.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$9.5M | -$5.4M | $70.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$8.2M | -$6.8M | $75.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$4.0M | -$5.4M | $83.6M | $18.4M | Needs four quarters | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-26 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 818 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.3% |
| 1 month | +18.7% |
| 3 months | -2.6% |
| Year to date | +45.7% |
| 1 year | +89.4% |
| From 52-week high | -13.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
| AUPH | Aurinia Pharmaceuticals Inc | $15.48 | -1.59% | $2.1B |
| SDGR | Schrodinger Inc. | $27.36 | -7.35% | $2.1B |
| PRGO | Perrigo Company plc | $16.18 | -0.37% | $2.2B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
| PHVS | Pharvaris N.V. | $32.44 | -2.76% | $2.3B |
| PBH | Prestige Consumer Healthcare Inc. | $48.00 | +3.92% | $2.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier